Shopping Cart 0
Cart Subtotal
USD 0

Alexion Pharmaceuticals Inc (ALXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological and autoimmune disorders. The company's marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company's research and development activities focus on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc (ALXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16

Venture Financing 17

Moderna Therapeutics Raises USD450 Million in Venture Financing 17

Wilson Therapeutics Raises USD 40 Million In Series B Financing 19

Private Equity 21

TRC Capital To Acquire 0.77% Stake In Alexion Pharma For USD 136 Million 21

Partnerships 22

Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22

Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24

X-Chem Enters into Discovery Agreement with Alexion Pharma 25

Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27

Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28

Licensing Agreements 29

Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29

Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31

Xencor Enters into Licensing Agreement with Alexion Pharma 32

Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34

Equity Offering 35

Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35

Wilson Therapeutics Raises USD48 Million in IPO 37

Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39

Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41

Synageva BioPharma Completes Public Offering Of Shares For USD 211.5 Million 42

Synageva BioPharma Completes Public Offering Of Shares For USD 179 Million 44

Synageva BioPharma Completes Public Offering Of Common Stock For USD 118 Million 46

Synageva BioPharma Completes Public Offering Of Common Stock For USD 115 Million 47

Synageva BioPharma Completes Public Offering Of Common Stock For USD 90 Million 49

Asset Transactions 51

BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51

Acquisition 52

Alexion Pharma Acquires Syntimmune 52

Alexion Acquires Wilson Therapeutics for USD852 Million 53

Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55

Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57

Alexion Pharma Completes Acquisition Of Enobia Pharma 58

Alexion Pharmaceuticals Inc-Key Competitors 60

Alexion Pharmaceuticals Inc-Key Employees 61

Alexion Pharmaceuticals Inc-Locations And Subsidiaries 62

Head Office 62

Other Locations & Subsidiaries 62

Recent Developments 65

Strategy And Business Planning 65

Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 65

Financial Announcements 67

Oct 24, 2018: Alexion reports third quarter 2018 results 67

Jul 26, 2018: Alexion Reports Second Quarter 2018 Results 69

Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study 71

Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018 73

Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 75

Apr 27, 2017: Alexion Reports First Quarter 2017 Results 76

Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 77

Corporate Communications 79

Feb 05, 2018: Alexion Pharmaceuticals Names Judith A. Reinsdorf As Board Director 79

Jan 22, 2018: Alexion Pharmaceuticals Names Deborah Dunsire As Board Director 80

Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 81

Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 82

Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 83

Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 84

May 23, 2017: Alexion Announces Executive Leadership Changes 86

Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 88

Mar 24, 2017: Alexion submits application to Japan's MHLW to extend Soliris indication to treat gMG 89

Mar 02, 2017: Leonard Bell, M.D., Alexion's Founder, Announces Plans to Retire as Chairman and Board Member 90

Product News 92

12/11/2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting 92

11/01/2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting 94

01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 95

Product Approvals 96

Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US 96

Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU) 98

Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S. 99

Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease 101

Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS 102

Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 103

Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 104

Clinical Trials 105

Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA) 105

Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology 106

Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting 108

Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting 110

Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naive Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 112

Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease 114

Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease 115

Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting 117

Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology 119

Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting 120

Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting 122

Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting 123

Apr 24, 2017: Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting 125

Apr 05, 2017: Final Phase 2 Results For WTX-101 Accepted As A Late-Breaker Presentation At EASL Annual Meeting 127

Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 128

Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 129

Other Significant Developments 130

Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 130

Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 131

Appendix 133

Methodology 133

About GlobalData 133

Contact Us 133

Disclaimer 133


List Of Figure

List of Figures

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16

Moderna Therapeutics Raises USD450 Million in Venture Financing 17

Wilson Therapeutics Raises USD 40 Million In Series B Financing 19

TRC Capital To Acquire 0.77% Stake In Alexion Pharma For USD 136 Million 21

Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22

Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24

X-Chem Enters into Discovery Agreement with Alexion Pharma 25

Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27

Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28

Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29

Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31

Xencor Enters into Licensing Agreement with Alexion Pharma 32

Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34

Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35

Wilson Therapeutics Raises USD48 Million in IPO 37

Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39

Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41

Synageva BioPharma Completes Public Offering Of Shares For USD 211.5 Million 42

Synageva BioPharma Completes Public Offering Of Shares For USD 179 Million 44

Synageva BioPharma Completes Public Offering Of Common Stock For USD 118 Million 46

Synageva BioPharma Completes Public Offering Of Common Stock For USD 115 Million 47

Synageva BioPharma Completes Public Offering Of Common Stock For USD 90 Million 49

BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51

Alexion Pharma Acquires Syntimmune 52

Alexion Acquires Wilson Therapeutics for USD852 Million 53

Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55

Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57

Alexion Pharma Completes Acquisition Of Enobia Pharma 58

Alexion Pharmaceuticals Inc, Key Competitors 60

Alexion Pharmaceuticals Inc, Key Employees 61

Alexion Pharmaceuticals Inc, Subsidiaries 62

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alexion Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological and autoimmune disorders. The company's marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company's research and development activities focus on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc (ALXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16

Venture Financing 17

Moderna Therapeutics Raises USD450 Million in Venture Financing 17

Wilson Therapeutics Raises USD 40 Million In Series B Financing 19

Private Equity 21

TRC Capital To Acquire 0.77% Stake In Alexion Pharma For USD 136 Million 21

Partnerships 22

Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22

Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24

X-Chem Enters into Discovery Agreement with Alexion Pharma 25

Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27

Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28

Licensing Agreements 29

Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29

Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31

Xencor Enters into Licensing Agreement with Alexion Pharma 32

Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34

Equity Offering 35

Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35

Wilson Therapeutics Raises USD48 Million in IPO 37

Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39

Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41

Synageva BioPharma Completes Public Offering Of Shares For USD 211.5 Million 42

Synageva BioPharma Completes Public Offering Of Shares For USD 179 Million 44

Synageva BioPharma Completes Public Offering Of Common Stock For USD 118 Million 46

Synageva BioPharma Completes Public Offering Of Common Stock For USD 115 Million 47

Synageva BioPharma Completes Public Offering Of Common Stock For USD 90 Million 49

Asset Transactions 51

BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51

Acquisition 52

Alexion Pharma Acquires Syntimmune 52

Alexion Acquires Wilson Therapeutics for USD852 Million 53

Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55

Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57

Alexion Pharma Completes Acquisition Of Enobia Pharma 58

Alexion Pharmaceuticals Inc-Key Competitors 60

Alexion Pharmaceuticals Inc-Key Employees 61

Alexion Pharmaceuticals Inc-Locations And Subsidiaries 62

Head Office 62

Other Locations & Subsidiaries 62

Recent Developments 65

Strategy And Business Planning 65

Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 65

Financial Announcements 67

Oct 24, 2018: Alexion reports third quarter 2018 results 67

Jul 26, 2018: Alexion Reports Second Quarter 2018 Results 69

Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study 71

Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018 73

Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 75

Apr 27, 2017: Alexion Reports First Quarter 2017 Results 76

Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 77

Corporate Communications 79

Feb 05, 2018: Alexion Pharmaceuticals Names Judith A. Reinsdorf As Board Director 79

Jan 22, 2018: Alexion Pharmaceuticals Names Deborah Dunsire As Board Director 80

Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 81

Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 82

Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 83

Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 84

May 23, 2017: Alexion Announces Executive Leadership Changes 86

Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 88

Mar 24, 2017: Alexion submits application to Japan's MHLW to extend Soliris indication to treat gMG 89

Mar 02, 2017: Leonard Bell, M.D., Alexion's Founder, Announces Plans to Retire as Chairman and Board Member 90

Product News 92

12/11/2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting 92

11/01/2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting 94

01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 95

Product Approvals 96

Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US 96

Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU) 98

Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S. 99

Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease 101

Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS 102

Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 103

Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 104

Clinical Trials 105

Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA) 105

Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology 106

Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting 108

Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting 110

Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naive Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 112

Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease 114

Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease 115

Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting 117

Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology 119

Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting 120

Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting 122

Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting 123

Apr 24, 2017: Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting 125

Apr 05, 2017: Final Phase 2 Results For WTX-101 Accepted As A Late-Breaker Presentation At EASL Annual Meeting 127

Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 128

Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 129

Other Significant Developments 130

Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 130

Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 131

Appendix 133

Methodology 133

About GlobalData 133

Contact Us 133

Disclaimer 133


List Of Figure

List of Figures

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16

Moderna Therapeutics Raises USD450 Million in Venture Financing 17

Wilson Therapeutics Raises USD 40 Million In Series B Financing 19

TRC Capital To Acquire 0.77% Stake In Alexion Pharma For USD 136 Million 21

Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22

Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24

X-Chem Enters into Discovery Agreement with Alexion Pharma 25

Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26

Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27

Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28

Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29

Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31

Xencor Enters into Licensing Agreement with Alexion Pharma 32

Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34

Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35

Wilson Therapeutics Raises USD48 Million in IPO 37

Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39

Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41

Synageva BioPharma Completes Public Offering Of Shares For USD 211.5 Million 42

Synageva BioPharma Completes Public Offering Of Shares For USD 179 Million 44

Synageva BioPharma Completes Public Offering Of Common Stock For USD 118 Million 46

Synageva BioPharma Completes Public Offering Of Common Stock For USD 115 Million 47

Synageva BioPharma Completes Public Offering Of Common Stock For USD 90 Million 49

BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51

Alexion Pharma Acquires Syntimmune 52

Alexion Acquires Wilson Therapeutics for USD852 Million 53

Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55

Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57

Alexion Pharma Completes Acquisition Of Enobia Pharma 58

Alexion Pharmaceuticals Inc, Key Competitors 60

Alexion Pharmaceuticals Inc, Key Employees 61

Alexion Pharmaceuticals Inc, Subsidiaries 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alexion Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.